NCT03131427 China Registry for Genetic / Metabolic Liver Diseases
| NCT ID | NCT03131427 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Friendship Hospital |
| Condition | Genetic/Metabolic Liver Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2015-06-13 |
| Primary Completion | 2022-04-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2015-06-13 with a primary completion date of 2022-04-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CR-GMLD registry started on June 13, 2015 to collect cases of genetic/metabolic liver diseases from tertiary or secondary hospitals in mainland China. Demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. Patients' whole blood and serum were collected for genetic testing and future researches. These patients will be followed-up every six to twelve months.
Eligibility Criteria
Inclusion Criteria: Patients who were diagnosed or possibly diagnosed with Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or other genetic/metabolic liver diseases. Exclusion Criteria: Patients who are unable or unwilling to provide informed consent.
Contact & Investigator
Jidong Jia, Doctor
PRINCIPAL INVESTIGATOR
Beijing Friendship Hospital
Frequently Asked Questions
Who can join the NCT03131427 clinical trial?
This trial is open to participants of all sexes, studying Genetic/Metabolic Liver Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03131427 currently recruiting?
Yes, NCT03131427 is actively recruiting participants. Contact the research team at jia_jd@ccmu.edu.cn for enrollment information.
Where is the NCT03131427 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Beijing, China, Beijing, China and 8 additional locations.
Who is sponsoring the NCT03131427 clinical trial?
NCT03131427 is sponsored by Beijing Friendship Hospital. The principal investigator is Jidong Jia, Doctor at Beijing Friendship Hospital. The trial plans to enroll 20,000 participants.